Skip to main content
Back
Watch Compare

Dare Bioscience, Inc.

Data quality: 100%
DARE
NASDAQ Manufacturing Chemicals
$1.80
▼ $0.04 (-1.91%)
Mkt Cap: 27.01 M
Price
$1.86
Mkt Cap
27.01 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Negative free cash flow of -10.27 M
Capital intensive — 37.40% of revenue goes to capex

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)10429.36%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
N/A
ROIC-650.73%
Net Margin-1300.66%
Op. Margin-1315.51%

Safety

Debt / Equity
N/A
Current Ratio1.18
Interest CoverageN/A

Valuation

PE (TTM|NTM|2027)
-2.02 | 3.13 | 3.18
Below sector avg (-1.49)
P/B Ratio9.45
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1385 peers)
Metric Stock Sector Median
P/E -2.0 -1.5
P/B 9.5 1.6
ROE % — -54.5
Net Margin % -1300.7 -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

Analyst Price Target

3 analysts
Buy
Current
$1.80
+438.5%
Target
$9.67
$8.00
$9.00
$12.00
Forecast
Forward P/E 3.13
Forward EPS $0.59
Est. Revenue 49.81 M

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 $0.59
-$0.59 – $1.76
 49.81 M 2
FY2026 -$1.21
-$1.50 – -$0.92
 271,500.0 2

Earnings Surprises

Last 4 quarters
Quarter Est. EPS Actual EPS Surprise
Q42025 -$0.42 -$0.10 +76.1%
Q32025 -$0.40 -$0.28 +30.0%
Q22025 -$0.58 -$0.45 +22.4%
Q12025 -$0.58 -$0.50 +13.8%

All Fundamental Metrics
Growth
Revenue Growth (1Y) 10429.36% Revenue Growth (3Y) -39.43%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1.03 M Net Income (TTM) -13.40 M
ROE N/A ROA -61.28%
Gross Margin N/A Operating Margin -1315.51%
Net Margin -1300.66% Free Cash Flow (TTM) -10.27 M
ROIC -650.73% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1.18
Interest Coverage N/A Asset Turnover 0.05
Working Capital 3.79 M Tangible Book Value 2.86 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2.02 Forward P/E 3.13
P/B Ratio 9.45 P/S Ratio 26.22
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 0.54 Fwd Earnings Yield 31.95%
FCF Yield -38.03%
Market Cap 27.01 M Enterprise Value 3.93 M
Per Share
EPS (Diluted TTM) -1.20 Revenue / Share 0.07
FCF / Share -0.71 OCF / Share -0.68
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 37.40% FCF Conversion 76.65%
SBC-Adj. FCF -11.93 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1.03 M 9,784.0 2.81 M 10.00 M —
Net Income -13.40 M -4.05 M -30.16 M -30.95 M -38.70 M
EPS (Diluted) -1.20 -0.48 -0.35 -0.37 -0.63
Gross Profit — — — — —
Operating Income -13.55 M -23.45 M -30.94 M -31.39 M -39.07 M
EBITDA — — — — —
R&D Expenses 5.52 M 14.21 M 21.54 M 30.04 M 30.62 M
SG&A Expenses 8.76 M — — — —
D&A 1.63 M — — — —
Interest Expense — — — — —
Income Tax 0.0 0.0 0.0 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 32.47 M 22.10 M 21.28 M 43.83 M 55.81 M
Total Liabilities 29.63 M 28.11 M 26.33 M 32.71 M 17.05 M
Shareholders' Equity 2.84 M -6.01 M -5.05 M 11.11 M 38.75 M
Total Debt — — — — —
Cash & Equivalents 24.71 M 15.70 M 10.48 M 34.67 M 51.67 M
Current Assets 27.06 M 18.45 M 17.54 M 43.04 M 55.30 M
Current Liabilities 23.69 M 21.61 M 20.48 M 31.62 M 16.05 M